Singapore accelerates multi-omics innovation in pharmaceutical sciences

Benefiting the broader healthcare ecosystem through enhanced drug discovery capabilities

image credit- freepik

MGI Tech Singapore, and the Department of Pharmacy and Pharmaceutical Sciences in the National University of Singapore’s Faculty of Science (NUS PPS) have announced a collaboration on a multi-omics laboratory.

As part of MGI’s global DCS Lab initiative, this joint effort integrates MGI’s cutting-edge genomic sequencing and multi-omics technologies into pharmaceutical education, research, and drug discovery.

Under this collaboration, MGI will support NUS PPS in establishing a high-performance multi-omics environment. The lab features an integrated instrument portfolio designed to provide deep insights across DNA genomics, cell omics, and spatial omics.

This suite of technology offers a streamlined and efficient workflow, enabling NUS PPS researchers to execute complex assignments across various omics layers for applications in precision medicine, drug discovery, and pharmaceutical sciences.

The lab is positioned to become a critical incubator for pharmaceutical innovation, ultimately benefiting the broader healthcare ecosystem through enhanced drug discovery capabilities.

Launched in 2023, MGI’s DCS Lab Initiative represents the company’s first global programme targeting international laboratories with a focus on frontier science. The initiative is named after MGI’s three core technologies: DNA genomics, cell omics, and spatial omics. To date, MGI has supported the establishment of more than 30 DCS labs worldwide, empowering scientists to push the boundaries of life science.